IQVIA Holdings Inc. (0JDM.L)
USD 147.96
(3.19%)
USD 147.96
(3.19%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.05 Billion USD | -35.86% |
| 2022 | 3.2 Billion USD | -0.84% |
| 2021 | 3.22 Billion USD | 4.94% |
| 2020 | 3.07 Billion USD | 4.77% |
| 2019 | 2.93 Billion USD | 2.77% |
| 2018 | 2.85 Billion USD | 9.21% |
| 2017 | 2.61 Billion USD | 101.23% |
| 2016 | 1.3 Billion USD | 41.15% |
| 2015 | 920.98 Million USD | 4.38% |
| 2014 | 882.33 Million USD | 2.54% |
| 2013 | 860.51 Million USD | 5.23% |
| 2012 | 817.75 Million USD | 7.27% |
| 2011 | 762.29 Million USD | 9.15% |
| 2010 | 698.4 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 800 Million USD | 62.67% |
| 2024 Q1 | 508 Million USD | -8.63% |
| 2024 Q2 | 509 Million USD | 0.2% |
| 2023 Q4 | 556 Million USD | -30.41% |
| 2023 Q3 | 799 Million USD | 7.83% |
| 2023 Q1 | 766 Million USD | -18.51% |
| 2023 Q2 | 741 Million USD | -3.26% |
| 2023 FY | 2.05 Billion USD | -35.86% |
| 2022 Q3 | 765 Million USD | 1.59% |
| 2022 Q1 | 743 Million USD | -7.59% |
| 2022 Q4 | 940 Million USD | 22.88% |
| 2022 Q2 | 753 Million USD | 1.35% |
| 2022 FY | 3.2 Billion USD | -0.84% |
| 2021 Q1 | 765 Million USD | -8.38% |
| 2021 Q2 | 825 Million USD | 7.84% |
| 2021 Q3 | 834 Million USD | 1.09% |
| 2021 FY | 3.22 Billion USD | 4.94% |
| 2021 Q4 | 804 Million USD | -3.6% |
| 2020 Q1 | 723 Million USD | -9.4% |
| 2020 Q4 | 835 Million USD | 7.19% |
| 2020 Q2 | 739 Million USD | 2.21% |
| 2020 Q3 | 779 Million USD | 5.41% |
| 2020 FY | 3.07 Billion USD | 4.77% |
| 2019 Q1 | 714 Million USD | -3.12% |
| 2019 FY | 2.93 Billion USD | 2.77% |
| 2019 Q2 | 730 Million USD | 2.24% |
| 2019 Q3 | 694 Million USD | -4.93% |
| 2019 Q4 | 798 Million USD | 14.99% |
| 2018 Q1 | 702 Million USD | -5.39% |
| 2018 FY | 2.85 Billion USD | 9.21% |
| 2018 Q4 | 737 Million USD | 3.51% |
| 2018 Q3 | 712 Million USD | 0.85% |
| 2018 Q2 | 706 Million USD | 0.57% |
| 2017 Q2 | 615 Million USD | 0.49% |
| 2017 Q1 | 612 Million USD | 5.52% |
| 2017 Q4 | 742 Million USD | 14.68% |
| 2017 Q3 | 647 Million USD | 5.2% |
| 2017 FY | 2.61 Billion USD | 101.23% |
| 2016 Q1 | 225.51 Million USD | -7.6% |
| 2016 Q3 | 233.64 Million USD | -6.75% |
| 2016 Q2 | 250.56 Million USD | 11.11% |
| 2016 FY | 1.3 Billion USD | 41.15% |
| 2016 Q4 | 580 Million USD | 148.24% |
| 2015 FY | 920.98 Million USD | 4.38% |
| 2015 Q4 | 244.06 Million USD | 5.47% |
| 2015 Q3 | 231.41 Million USD | 2.44% |
| 2015 Q2 | 225.89 Million USD | 2.87% |
| 2015 Q1 | 219.6 Million USD | -2.42% |
| 2014 Q4 | 225.05 Million USD | 2.75% |
| 2014 Q3 | 219.02 Million USD | 0.01% |
| 2014 Q1 | 219.24 Million USD | -5.82% |
| 2014 FY | 882.33 Million USD | 2.54% |
| 2014 Q2 | 219.01 Million USD | -0.1% |
| 2013 Q3 | 199.57 Million USD | -12.79% |
| 2013 Q4 | 232.79 Million USD | 16.65% |
| 2013 FY | 860.51 Million USD | 5.23% |
| 2013 Q1 | 199.3 Million USD | -7.57% |
| 2013 Q2 | 228.83 Million USD | 14.82% |
| 2012 Q1 | 205.79 Million USD | 0.0% |
| 2012 Q3 | 192.78 Million USD | -5.29% |
| 2012 Q4 | 215.63 Million USD | 11.86% |
| 2012 FY | 817.75 Million USD | 7.27% |
| 2012 Q2 | 203.54 Million USD | -1.09% |
| 2011 FY | 762.29 Million USD | 9.15% |
| 2010 FY | 698.4 Million USD | 0.0% |
| 2001 Q3 | 517 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 79.979% |
| Dynavax Technologies Corporation | 219.14 Million USD | -836.823% |
| Illumina, Inc. | 3.81 Billion USD | 46.158% |
| Biogen Inc. | 5.2 Billion USD | 60.556% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -355.218% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | -88.454% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | -50.865% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | -288.083% |
| Waters Corporation | 943.51 Million USD | -117.59% |
| Perrigo Company plc | 1.52 Billion USD | -34.315% |
| uniQure N.V. | 285.08 Million USD | -620.134% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -402.194% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -380.064% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -644.669% |
| bluebird bio, Inc. | 240.23 Million USD | -754.591% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -1341.076% |
| Imunon, Inc. | 21.03 Million USD | -9662.045% |
| Myriad Genetics, Inc. | 600.1 Million USD | -242.11% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | -28.594% |
| Nektar Therapeutics | 190.9 Million USD | -975.415% |
| Editas Medicine, Inc. | 247.3 Million USD | -730.152% |
| Verastem, Inc. | 92.08 Million USD | -2129.486% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 94.943% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -14659.547% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -1601.518% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -4496.234% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | -17.565% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -797.761% |
| Evolus, Inc. | 189.75 Million USD | -981.899% |
| Adicet Bio, Inc. | 152.03 Million USD | -1250.32% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -16809.645% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 27.077% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -655.065% |
| FibroGen, Inc. | 398.11 Million USD | -415.683% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 2.931% |
| OPKO Health, Inc. | 574.68 Million USD | -257.239% |
| Homology Medicines, Inc. | 9.87 Million USD | -20689.873% |
| Geron Corporation | 70.44 Million USD | -2814.496% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | -14.052% |
| Exelixis, Inc. | 1.58 Billion USD | -29.382% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -1936.161% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -3582.115% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | -272.213% |
| Zoetis Inc. | 2.76 Billion USD | 25.75% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -330.977% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -4132.815% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 57.005% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -5143.532% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | -163.345% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -456.954% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -585.893% |
| Blueprint Medicines Corporation | 722.86 Million USD | -184.01% |
| Insmed Incorporated | 949.26 Million USD | -116.274% |
| TG Therapeutics, Inc. | 198.47 Million USD | -934.387% |
| Incyte Corporation | 1.19 Billion USD | -72.449% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -96.648% |